Results 311 to 320 of about 457,473 (371)

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Immune Evasion of Helicobacter pylori and Extra‐Gastric Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Helicobacter pylori (H. pylori) is a group 1 gastric carcinogen that plays a significant role in extra‐gastric digestive system cancers. H. pylori disrupts host cell homeostasis through expression of virulence factors leading to immune evasion as well as persistent gastric mucosal colonization. H. pylori infection has been shown to play a role
Evren Doruk Engin, Ayse Basak Engin, Atilla Engin   +2 more
wiley   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, Wan Chee Ong, Vineet Ahuja, Satimai Aniwan, Ryota Hokari, Wei Jie Jonathan Lee, Alex Hwong‐Ruey Leow, Wai‐Keung Leung, Wee‐Chian Lim, Govind Makharia, Katsuyoshi Matsuoka, Nazri Mustaffa, Siew‐Chien Ng, Mathew Philip, Pises Pisespongsa, Raja Affendi Raja Ali, Zhi Hua Ran, Marcellus Simadibrata, Jose Sollano, Malcolm Tan, Hang Dao Viet, Nik Razima Wan Ibrahim, Kai Chun Wu, Byong Duk Ye, Ida Hilmi, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD)   +34 more
wiley   +1 more source

Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Javier Ortiz de Frutos, Juan Francisco Silvestre, Brian Esparza, Daniela E. Myers, Pinaki Biswas, Irene Hernández‐Martín, Erman Güler, Marina Mikheil, Raj Chovatiya   +10 more
wiley   +1 more source

Systemic, Lifestyle and Environmental Modifying Factors in the Pathogenesis of Periodontitis

Journal of Periodontal Research, EarlyView.
A variety of impacting factors in the pathogenesis of periodontitis exist, including systemic, lifestyle, and environmental factors. This review highlights the manifold mechanistic aspects of the link between the pathogenesis of periodontitis, addressing these numerous factors to supplement the long‐standing knowledge of the progression of the disease.
Groeger Sabine Elisabeth, Zhou Yuxi, Yong Jiawen, Wang Lei, Ruf Sabine, Meyle Joerg   +5 more
wiley   +1 more source

Inflammatory and Immunological Basis of Periodontal Diseases

Journal of Periodontal Research, EarlyView.
The periodontal lesion emerges as an evolving immunological battlefield, where host–microbiome interactions, dysregulated immune responses, fragile resolution mechanisms, and inflammophilic dysbiosis converge to shift the balance from homeostasis to unrestrained tissue destruction.
Giacomo Baima, Marion Arce, Mario Romandini, Thomas Van Dyke   +3 more
wiley   +1 more source

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer, Melinda J. Gooderham, Michael Sebastian, David Rosmarin, Andrew Blauvelt, Maryam Shayesteh Alam, Jacek Zdybski, Shaoceng Wei, Deanna Kornacki, Thierry Passeron, John E. Harris   +10 more
wiley   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

Postgraduate Medicine, 2013
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovsek,,, of Medicine
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

Journal of Medicinal Chemistry, 2020
In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors.
Tao Yang, Mengshi Hu, Yong Chen, Mingli Xiang, Ming-hai Tang, Wenyan Qi, Mingsong Shi, Jun He, X. Yuan, Chufeng Zhang, Kongjun Liu, Jiewen Li, Zhuang Yang, Lijuan Chen   +13 more
semanticscholar   +1 more source

Downregulation of KCNQ4 by Janus Kinase 2

The Journal of Membrane Biology, 2013
Janus kinase-2 (JAK2) participates in the signaling of several hormones, growth factors and cytokines. Further stimulators of JAK2 include osmotic cell shrinkage, and the kinase activates the cell volume regulatory Na(+)/H(+) exchanger. The kinase may thus participate in cell volume regulation. Cell shrinkage is known to inhibit K(+) channels.
Hosseinzadeh, Zohreh, Sopjani, Mentor, Pakladok, Tatsiana, Bhavsar, Shefalee K., Lang, Florian   +4 more
openaire   +3 more sources